Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05103904 · ClinicalTrials.gov registry record · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
A Phase 2 study of Stage III Hepatocellular Carcinoma AJCC v8 and Stage IV Hepatocellular Carcinoma AJCC v8, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 3
- Study locations
NCT05103904 is a Phase 2 study of Stage III Hepatocellular Carcinoma AJCC v8 and Stage IV Hepatocellular Carcinoma AJCC v8 that is actively recruiting participants, run by Emory University. The registered enrollment target is 19 participants, below the 58-participant average among 14 other Stage III Hepatocellular Carcinoma AJCC v8 trials with a reported enrollment target (67% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05103904, a Phase 2 study of Stage III Hepatocellular Carcinoma AJCC v8 and Stage IV Hepatocellular Carcinoma AJCC v8, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is the second leading cause of cancer-related deaths in the world. Liver transplantation is a potentially curative treatment option for HCC, however, up to 20% of patients develop recurrent disease after liver transplantation and prognosis remains poor. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Systemic treatments for HCC have not been studied in patients with recurrent HCC after liver transplantation, so there is no established therapy for these patients. This phase II trial evaluates lenvatinib for this purpose.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Lenvatinib
Study Locations (3)
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Arizona - Scottsdale
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2026-11-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05103904
The ClinicalTrials.gov registry entry for NCT05103904 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 14 other Stage III Hepatocellular Carcinoma AJCC v8 trials with a reported enrollment target (67% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Stage III Hepatocellular Carcinoma AJCC v8 appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT05103904 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Arizona, Georgia.
Frequently Asked Questions
What is clinical trial NCT05103904 about?
NCT05103904 is a clinical study titled "Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant". This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is the second leading cause of cancer-related deaths in the world. Liver transplantation is a potentially curative tr...
What is the current status of trial NCT05103904?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2022-04-19. Estimated completion is 2026-11-04.
What conditions does trial NCT05103904 study?
This clinical trial studies the following conditions: Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma AJCC V8, Stage IVA Hepatocellular Carcinoma AJCC V8.
What interventions are being tested in trial NCT05103904?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT05103904?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05103904 being conducted?
This trial has 3 study locations across Alabama, Arizona, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Hepatocellular Carcinoma AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
RECRUITING · Phase 2
-
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
RECRUITING · Phase 2
-
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
RECRUITING · Phase 2
-
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Stage III Hepatocellular Carcinoma AJCC v8
All registered trials for this condition
Stage IV Hepatocellular Carcinoma AJCC v8
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.